ECM
ATNM icon

Endurant Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Endurant Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000,000
Closed -$15.2M – 61
2021
Q1 		$15.2M Buy
+2,000,000
New +$17M 3.97% 3

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Endurant Capital Management's ATNM Position: Q1 2023 in Review

Endurant Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2023, closing a stake of 45,612 shares — an estimated $486K sold.

Endurant Capital Management first reported a position in ATNM in Q2 2019 and held it in 5 quarters. The position peaked at $610K in Q2 2019. 64 funds tracked by Wall St. Rank hold ATNM as of Q1 2023.

  • Endurant Capital Management reported no remaining Actinium Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 45,612 Actinium Pharmaceuticals shares in Q1 2023, an estimated $486K.
  • Endurant Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2019 and held it in 5 quarters.
  • Endurant Capital Management's Actinium Pharmaceuticals position peaked at $610K in Q2 2019.
  • 64 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.